Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boehringer Targets High Unmet Need With Spesolimab Filing

Could Be First EU Approved Drug For Generalized Pustular Psoriasis Flares

Executive Summary

Boehringer Ingelheim files spesolimab in the EU, where it is a forerunner in the race to fill the unmet need in generalized pustular psoriasis flares.

You may also be interested in...



Boehringer’s Spesolimab Wins First Approval In Rare Skin Condition

The German firm’s monoclonal antibody has received a US thumbs-up for a severe skin disease with high unmet need but it must address diagnostic and educational hurdles.

AnaptysBio’s Imsidolimab Meets Yet Another Failure

The company is discontinuing the drug’s development in hidradenitis suppurativa after a Phase II flop, leaving GPP as the only viable indication, for which it is planning to out-license the drug.

Beware The Ides of March? AnaptysBio's Imsidolimab Has Another Trial Failure

After the 14 March announcement that the IL-36R agonist failed in an acne study, it appears to have better chances in generalized pustular psoriasis, an underserved orphan indication where the target is already validated.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel